Search

Your search keyword '"Consoli, U"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Consoli, U" Remove constraint Author: "Consoli, U"
200 results on '"Consoli, U"'

Search Results

1. Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

2. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)

3. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

5. P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

6. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

7. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

8. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

9. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

10. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

11. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

12. Cellular and molecular effects of protons: Apoptosis induction and potential implications for cancer therapy

13. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

17. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

18. SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS

19. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

20. PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL-LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK

21. DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI

22. PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

23. PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

24. PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI

25. PREDICTIVE VALUE OF END-OF-TREATMENT POSITRON EMISSION TOMOGRAPHY SCAN AFTER DA-EPOCH-R IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA. REAL-LIFE EXPERIENCE

26. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

27. TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA

28. IMATINIB FIRST-LINE WITH SWITCH TO 2ND GENERATION TYROSINE KINASE INHIBITORS IN CASE OF FAILURE OR TOXICITY: REAL-LIFE DATA FROM A POPULATION-BASED REGISTRY OF BCR-ABL1+CML PATIENTS

29. A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY

30. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

32. Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

34. DIAGNOSTIC POTENTIAL OF CD38 COMBINED WITH ZAP70 EXPRESSION IN PREDICTING MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE REGION IN CHRONIC LYMPHOCYTIC LEUKEMIA: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1- GISL STUDY

35. INCIDENCE OF CYTOGENETIC ABNORMALITIES IN NEWLY DIAGNOSED BINET STAGE A B-CLL AND RELATIONSHIP WITH PROGNSOTIC BIOMARKERS: PRELIMINARY RESULTS ON 240 PATIENTS INCLUDED IN THE PROSPECTIVE, MULTICENTER O-CLL1 GISL STUDY

36. Enhanced Percent Age of Leu M3+Dr+and Leu M3+Cd25+Cells in Newly Diagnosed Iddm Patients

38. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients

Catalog

Books, media, physical & digital resources